Trial Search Results

Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders

This research aims to identify efficacious strategies for treating tobacco dependence among adolescent smokers with co-occurring psychiatric disorders. Adolescent smoking remains a significant public health issue with 23% of high school students reporting smoking a cigarette in the past month1. Smoking rates are two to four times higher among adolescents with psychiatric disorders such as attention deficit disorders, conduct disorder, depression, anxiety disorders, and alcohol and illicit drug dependencies2-4.

Empirical investigations of adolescent tobacco treatment interventions number less than 50 with many of the studies criticized for methodological problems (i.e., follow up < 6 months, poor retention, lack of control or comparison groups)2,5, 6. There have been no unequivocal successes; however, promising interventions include stage-based, cognitive behavioral (CBT), and multicomponent treatments2, 7. Additionally, the nicotine patch is well tolerated and safe among adolescents8 and rarely abused9. Less than a third of adolescent tobacco users report intention to quit in the near future2, 10, 11; thus, it seems critical that cessation interventions for this complex group be designed to assist smokers at all stages of readiness through the quitting process. A stepped care approach has the potential of matching more intensive services to those ready for and in need of greater treatment. Interventions delivered in health care settings have the appeal of broad reach.

The primary specific aims of this research are to evaluate, in a randomized clinical trial (N=160), the efficacy of a stepped care intervention for treating smoking among adolescents recruited from outpatient psychiatry settings. To our knowledge, this would be the first study to examine outpatient psychiatry settings for treating tobacco dependence in adolescents. The stepped care intervention combines expert-system contacts, individual CBT sessions, and 12-weeks of nicotine replacement therapy (NRT).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

University of California, San Francisco

Collaborator: National Institute on Drug Abuse (NIDA)

Stanford Investigator(s):


  • Behavioral: Tobacco Use Cessation


Phase 3


Inclusion Criteria:

   - receiving active outpatient psychiatric care

   - report smoking at least 1 cigarette in the previous 30 days and at least 100
   cigarettes in their lifetime

   - Other inclusion criteria are: no plan to relocate outside of the greater San Francisco
   Bay Area in the next 12 months and telephone access for scheduling follow up

Exclusion Criteria:

   - cognitive impairment precluding ability to participate

   - non-English speaking

   - currently engaged in tobacco treatment

   - Recruitment of acutely psychotic, manic, or hostile patients will be delayed until
   there is significant reduction of these symptoms and patients are able to assent to
   study participation

Ages Eligible for Study

13 Years - 25 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting